The prognostic role of phospho-Src family kinase analysis in tongue cancer
- First Online:
- 88 Downloads
The up regulation of Phospho-Src family kinase oncogene has been correlated with reduced post-operative survival in various cancers but never in tongue cancer.
We analyzed phospho-Src family kinase in 39 tongue (mobile) cancer patients by immunohistochemistry, compared these results with similar analysis for TUNEL and c-erbB-2 and with both clinical tumor characteristics and patient survival probability rates.
Phospho-Src family kinase overexpression was found in most tongue cancer biopsies (62%), significantly correlating with tumors larger in size (P = 0.05), progression—lymph node metastasis (0.004) and stage (P = 0.05), and correlating with TUNEL (P = 0.01) and c-erbB-2 (P = 0.05) expression rates. At 60 months, survival probability for negative phospho-Src family kinase level (=0) patients was 67%, but 30% for positive phospho-Src family kinase level (>0) patients (P = 0.05).
Inverse correlation between phospho-Src family kinase and patient survival demonstrates the prognostic role of phospho-Src family kinase in tongue cancer. These findings suggest a novel link between phospho-Src family kinase and TUNEL and c-erbB-2 pathways, tilting the balance toward cell proliferation.
KeywordsPhospho-Src family kinase Oncogene Tongue Cancer Tumor marker Prognosis
- Muir C, Weiland L (1995) Upper aerodigestive tract cancers. Cancer 75:147–153. doi:10.1002/1097-0142(19950101)75:1+<147::AID-CNCR2820751304>3.0.CO;2-U CrossRefPubMedGoogle Scholar
- Nagler RM, Barak M, Ben-Aryeh H, Peled M, Filatov M, Laufer D (1999) Early diagnostic and treatment monitoring role of Cyfra 21–1 and TPS in oral squamous cell carcinoma. Cancer 35:1018–1025. doi:10.1002/(SICI)1097-0142(19990301)85:5<1018::AID-CNCR2>3.0.CO;2-R CrossRefGoogle Scholar
- Tamura I, Sakaki T, Chaqour B, Howard PS, Ikeo T, Macarak EJ (2003) Correlation of P-cadherin and beta-catenin expression and phosphorylation with carcinogenesis in rat tongue cancer induced with 4-nitroquinoline 1-oxide. Oral Oncol 39:506–514. doi:10.1016/S1368-8375(03)00013-7 CrossRefPubMedGoogle Scholar
- Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H, Clarke RB, Dive C, Bundred NJ (2006) Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 95:1410–1414. doi:10.1038/sj.bjc.6603444 CrossRefPubMedGoogle Scholar
- Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189PubMedGoogle Scholar
- Yeole BB, Sankaranarayanan R, Sunny M, Sc L, Swaminathan R, Parkin DM (2000) Survival from head and neck cancer in Mumbai (Bombay), India. Cancer 89:437–444. doi:10.1002/1097-0142(20000715)89:2<437::AID-CNCR32>3.0.CO;2-R CrossRefPubMedGoogle Scholar